EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

References

• Schmidt L, Wild C. Assessing the public and philanthropic financial contribution to the development of new drugs: a bibliographic analysis. Sci Technol Public Policy 2020;4(1):8–14. https://doi.org/10.11648/j.stpp.20200401.12.
   Google Scholar
• Chakravarthy, R, Cotter, K, DiMasi, J, Milne, CP, Wendel, N, Public- and private-sector contributions to the research and development of the most transformational drugs in the past 25 years: from theory to therapy.Ther Innov Regul Sci. 2016;50(6):759–68. https://doi.org/10.1177/2168479016648730.
   PubMed Web of Science ®Google Scholar
• Morgan, SG, Bathula, HS, Moon, S, Pricing of pharmaceuticals is becoming a major challenge for health systems.BMJ. 2020;368:I4627. https://doi.org/10.1136/bmj.l4627.
   PubMed Web of Science ®Google Scholar
• Boldrin M, Levine D. The pharmaceutical industry. In: Against intellectual monopoly. 2008:212–242. https://doi.org/10.1017/CBO9780511510854.
   Google Scholar
• Nayak, RK, Avorn, J, Kesselheim, AS, Public sector financial support for late stage discovery of new drugs in the United States: cohort study.BMJ. 2019;367:I5766. https://doi.org/10.1136/bmj.l5766.
   Google Scholar
• Kneller, R, The importance of new companies for drug discovery: origins of a decade of new drugs.Nat Rev Drug Discov. 2010;9(11):867–82. https://doi.org/10.1038/nrd3251.
   PubMed Web of Science ®Google Scholar
• Cockburn, I, Henderson, R, Public–private interaction in pharmaceutical research.Proc Natl Acad Sci USA. 1996;93(23):12725–30. https://doi.org/10.1073/pnas.93.23.12725.
   PubMed Web of Science ®Google Scholar
• Jayasundara, K, Hollis, A, Krahn, M, Mamdani, M, Hoch, JS, Grootendorst, P, Estimating the clinical cost of drug development for orphan versus non-orphan drugs.Orphanet J Rare Dis. 2019;14(1):12. https://doi.org/10.1186/s13023-018-0990-4.
   PubMed Web of Science ®Google Scholar
• European Commission (EC). Commitment and Coherenc e–Ex‐Post Evaluation of the 7th EU Framework Programme (2007–2013. 2015. https://ec.europa.eu/research/evaluations/pdf/fp7_final_evaluation_expert_group_report.pdf. Accessed 7 Jan 2021.
   Google Scholar
• EU Open Data Portal. CORDIS—EU research projects under FP7 (2007–2013). 2020. https://data.europa.eu/euodp/en/data/dataset/cordisfp7projects. Accessed 7 Jan 2021.
   Google Scholar
• Bailey, JR, Barnes, E, Cox, AL, Approaches, progress, and challenges to hepatitis C vaccine development.Gastroenterology. 2019;156(2):418–30. https://doi.org/10.1053/j.gastro.2018.08.060.
   PubMed Web of Science ®Google Scholar
• Baumert, TF, Fauvelle, C, Chen, DY, Lauer, GM, A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.J Hepatol. 2014;61(1 Suppl):S34–44. https://doi.org/10.1016/j.jhep.2014.09.009.
   PubMed Web of Science ®Google Scholar
• Duncan JD, Urbanowicz RA, Tarr AW and Ball JK. Hepatitis C virus vaccine: challenges and prospects. Vaccines (Basel). 2020. https://doi.org/10.3390/vaccines8010090.
   Google Scholar
• Holme, E, Lindstedt, S, Diagnosis and management of tyrosinemia type I.Curr Opin Pediatr. 1995;7(6):726–32. https://doi.org/10.1097/00008480-199512000-00017.
   PubMedGoogle Scholar
• Lock, E, Ranganath, LR, Timmis, O, The role of nitisinone in tyrosine pathway disorders.Curr Rheumatol Rep. 2014;16(11):457. https://doi.org/10.1007/s11926-014-0457-0.
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health. Therapeutic Goods Administration (TGA). Australian Public Assessment Report for Nitisinone. 2011. https://www.tga.gov.au/sites/default/files/auspar-orfadin.pdf. Accessed 7 Jan 2021.
   Google Scholar
• Center for Drug Evaluation and Research (CDER). NDA-21-232. Orfadin^TM (nitisinone). 2002. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-232_ORFADIN_medr.pdf. Accessed 7 Jan 2021.
   Google Scholar
• European Medicines Agency (EMA). Orfadin: EPAR—Scientific Discussion. 2005. https://www.ema.europa.eu/en/documents/scientific-discussion/orfadin-epar-scientific-discussion_en.pdf. Accessed 7 Jan 2021.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Clinical Review Report Nitisinone (Orfadin). 2018. https://www.cadth.ca/sites/default/files/cdr/clinical/SR0531_Orfadin_CL_Report.pdf. Accessed 7 Jan 2021.
   Google Scholar
• National Institute for Health Research (NIHR) Innovation Observatory. Nitisinone for Alkaptonuria. 2019. http://www.io.nihr.ac.uk/wp-content/uploads/2019/08/13330-Nitisinone-for-Alkaptonuria-V1.0-AUG2019-NON-CONF.pdf. Accessed 7 Jan 2021.
   Google Scholar
• Atcheson, E, Li, W, Bliss, CM, Chinnakannan, S, Heim, K, Sharpe, H, et al.Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunization strategies for hepatitis C Virus.Hepatology. 2020;71(3):794–807. https://doi.org/10.1002/hep.30894.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (GSK). GSK strengthens vaccines business with acquisition of Okairos. 2013. https://www.gsk.com/en-gb/media/press-releases/gsk-strengthens-vaccines-business-with-acquisition-of-okairos/#:~:text=GSK%20today%20announced%20that%20it,%2F%24325%20million)%20in%20cash. Accessed 7 Jan 2021.
   Google Scholar
• The National Institute of Allergy and Infectious Diseases (NIAID). Okairos’ hepatitis C vaccine fails to show effectiveness in trial. 2019. https://www.clinicaltrialsarena.com/news/niaid-okairos-hepatitis-c-vaccine-trial/. Accessed 7 Jan 2021.
   Google Scholar
• GlaxoSmithKline (GSK). Annual Report. 2019. https://www.gsk.com/media/5894/annual-report.pdf. Accessed 7 Jan 2021.
   Google Scholar
• Swedish Orphan Biovitrum AB (Sobi). Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU. 2020. https://www.sobi.com/en/press-releases/orfadinr-nitisinone-receives-positive-opinion-chmp-treatment-aku-1844542. Accessed 7 Jan 2021.
   Google Scholar
• Holme, E, Lindstedt, S, Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).J Inherit Metab Dis. 1998;21(5):507–517. https://doi.org/10.1023/A:1005410820201.
   PubMed Web of Science ®Google Scholar
• Larochelle, J, Alvarez, F, Bussières, JF, Chevalier, I, Dallaire, L, Dubois, J, et al.Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.Mol Genet Metab. 2012;107(1–2):49–54. https://doi.org/10.1016/j.ymgme.2012.05.022.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Orfadin: EPAR—Product Information. 2020. https://www.ema.europa.eu/en/documents/product-information/orfadin-epar-product-information_en.pdf. Accessed 13 Jan 2021.
   Google Scholar
• Warenverzeichnis Apothekerverlag Online. 2020. http://warenverzeichnis.apoverlag.at/. Accessed 04 Jan 2021.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Pharmacoeconomic Review Report Nitisinone (Orfadin). 2018. https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0531_Orfadin_PE_Report.pdf. Accessed 7 Jan 2021.
   Google Scholar
• Institute of Medicine (IOM). Breakthrough business models: drug development for rare and neglected diseases and individualized therapies: workshop summary. Washington, DC: The National Academies Press; 2009.
   Google Scholar
• Gallo, F, Seniori Costantini, A, Puglisi, M, Barton, N, Biomedical and health research: an analysis of country participation and research fields in the EU’s Horizon 2020.Eur J Epidemiol. 2020. https://doi.org/10.1007/s10654-020-00690-9.
   PubMed Web of Science ®Google Scholar
• Directorate-General for Parliamentary Research Services (European Parliament). EU Framework Programs for Research and Innovation. Evolution and key data from FP1 to Horizon 2020 in view of FP9: in-depth analysis. 2018. https://doi.org/10.2861/60724.
   Google Scholar
• Sarpatwari, A, Avorn, J, Kesselheim, AS. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?.BMJ. 2020;371:m3841. https://doi.org/10.1136/bmj.m3841.
   PubMedGoogle Scholar
• DiMasi, JA, Grabowski, HG, Hansen, RW. Innovation in the pharmaceutical industry: New estimates of R&D costs.J Health Econ. 2016;47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Gotham, D, McKenna, L, Frick, M, Lessem, E. Public investments in the clinical development of bedaquiline.PLoS ONE. 2020;15(9):e0239118. https://doi.org/10.1371/journal.pone.0239118.
   PubMed Web of Science ®Google Scholar
• Avorn J. The $2.6 billion pill—methodologic and policy considerations. N Engl J Med. 2015;372(20):1877–79. https://doi.org/10.1056/NEJMp1500848.
   Google Scholar